These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Some considerations on the prevalence of MDMA use. Newmeyer JA J Psychoactive Drugs; 1986; 18(4):361-2. PubMed ID: 2880952 [No Abstract] [Full Text] [Related]
24. Psychotherapy with psychedelic drugs: a case report. Di Leo FB J Psychoactive Drugs; 1981; 13(4):319-24. PubMed ID: 7338742 [No Abstract] [Full Text] [Related]
25. Structure-activity relationships of MDMA-like substances. Nichols DE; Oberlender R NIDA Res Monogr; 1989; 94():1-29. PubMed ID: 2575223 [No Abstract] [Full Text] [Related]
26. MDMA (3,4-methylenedioxymethamphetamine): proceedings of the conference. May 17-18, 1986, Oakland, California. J Psychoactive Drugs; 1986; 18(4):287-379. PubMed ID: 2880942 [No Abstract] [Full Text] [Related]
28. Incidence of recreational use of 3,4-methylenedimethoxymethamphetamine (MDMA, "ecstasy") on an undergraduate campus. Peroutka SJ N Engl J Med; 1987 Dec; 317(24):1542-3. PubMed ID: 2891034 [No Abstract] [Full Text] [Related]
30. Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Rattray M Essays Biochem; 1991; 26():77-87. PubMed ID: 1685707 [No Abstract] [Full Text] [Related]
31. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Screaton GR; Singer M; Cairns HS; Thrasher A; Sarner M; Cohen SL Lancet; 1992 Mar; 339(8794):677-8. PubMed ID: 1347361 [No Abstract] [Full Text] [Related]
32. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy'). Brown C; Osterloh J JAMA; 1987 Aug; 258(6):780-1. PubMed ID: 2886672 [No Abstract] [Full Text] [Related]
33. Subarachnoid haemorrhage associated with MDMA abuse. Gledhill JA; Moore DF; Bell D; Henry JA J Neurol Neurosurg Psychiatry; 1993 Sep; 56(9):1036-7. PubMed ID: 8105032 [No Abstract] [Full Text] [Related]
34. Spectrophotometric and liquid chromatographic identification of 3,4-methylenedioxyphenylisopropylamine and its N-methyl and N-ethyl homologs. Noggle FT; DeRuiter J; Long MJ J Assoc Off Anal Chem; 1986; 69(4):681-6. PubMed ID: 2875058 [TBL] [Abstract][Full Text] [Related]
35. The scheduling of MDMA: a pharmacist's perspective. Riedlinger JE J Psychoactive Drugs; 1985; 17(3):167-71. PubMed ID: 2865343 [No Abstract] [Full Text] [Related]
37. Responses to i.v. L-tryptophan in MDMA users. Price LH; Ricaurte GA; Krystal JH; Heninger GR NIDA Res Monogr; 1989; 95():421-2. PubMed ID: 2577044 [No Abstract] [Full Text] [Related]
38. A bit on the Wilde side: MDMA abuse. Mack RB N C Med J; 1985 Dec; 46(12):641-2. PubMed ID: 2867475 [No Abstract] [Full Text] [Related]
39. [Studies on the identification of psychotropic substances (VII). Preparation and various analytical data of standard references of some hallucinogens, 3,4-methylenedioxyamphetamine (MDA), 3,4- methylenedioxymethamphetamine (MDMA) and 5-methoxy-3,4- methylenedioxyamphetamine (MMDA)]. Shimamine M; Takahashi K; Nakahara Y Eisei Shikenjo Hokoku; 1990; (108):118-25. PubMed ID: 1364339 [TBL] [Abstract][Full Text] [Related]